Activity of gemcitabine in platinum-resistant ovarian germ cell cancer [3]

European Journal of Cancer Part A

Volumn 32, Issue 8, 1996, Pages 1437-1438

  Maas, K ^a   Daikeler, T ^a   Kanz, L ^a   Bokemeyer, C ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; GEMCITABINE; PACLITAXEL; VINBLASTINE;

ADULT; CANCER REGRESSION; CASE REPORT; DRUG EFFICACY; FEMALE; GERM CELL TUMOR; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETTER; NEUTROPENIA; OVARY CARCINOMA; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0030017996     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00128-1     Document Type: Letter

References (6)

1. Gershenson DM. Management of early ovarian cancer: germ cell and sex cord-stromal tumors. Gynecol Oncol 1994, 55, S62-S72.
2. Gershenson DM. Update on malignant ovarian germ cell tumors. Cancer 1993, 71, 1581-1590.
3. Bokemeyer C, Beyer J, Metzner B, et al. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 1996, in press.
4. Motzer RJ, Bajorin DF, Schwartz LH, et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 1994, 12, 2277-2283.
5. Lund B, Hansen OP, Theilade K, Hansen M, Neijt JP. Phase II study of gemcitabine (2′-2′-difluorodeoxycitidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 1994, 86, 1530-1533.
6. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994, 12, 1821-1826.